In troduc tion HIV infection was first reported in 1981 in USA. It has been 20 years since then. Owing to the understanding of the pathogenesis of this disease and development of new drugs such as HIV-specific protease inhibitor (PI), the prognosis of the disease has been improving. Especially after 1997 in Japan, the strategy of anti-HIV treatment shifted from a two-drug combination to a three-drug combination, which is called highly active antiretroviral therapy (HAART).HAART has been so effective that the prevalence of HIV-associated opportunistic infections has decreased dramatically ( Fig. 1 ). Mortality among hospitalized HIV-1 -infected patients in ACChas also decreased from 6.7% in 1996 to 2.6% since then ( Fig. 2 ). However, 80% of patients receiving HAARTsuffered from side effects and in 15% of these patients, it was necessary to change their treatment due to side effects. Furthermore, an unexpected side effect, namely lipodystrophy syndrome (LDS), emerged among patients whowere receiving HAART for more than one year. LDSwas first reported as re-distribution of lipid such as cen- Figure 1 . Annual prevalence of opportunistic infections in AGC, tral obesity with or without lipo-atrophy from extremities and/ or face. Not only cosmetic change, but also it is associated with an elevation of lipid and glucose levels. Therefore, patients with LDSface risk of ischemic heart diseases. Our survey indicated that the rate of LDSin Japanese patients was almost the same as that of Caucasianpatients reported elsewhere (1).
Drug resistance
HIV infection has been well controlled by HAARTbut it does not meancure. Patients on HAART must adhere to their treatment completely, otherwise resistant virus can appear in their clinical course (2), causing treatment failure (3). Therefore, an assay to detect the resistant virus has becomeimportant clinically, although it is likely very expensive. Current meansof detection of drug resistance are classified into three methods; genotypic, phenotypic (4), and recombinant virus assays. Amongthem, the genotypic assay is widely used in many laboratories because it is relatively rapid and easy. In order to investigate the indicative point of the assay, we prospectively examined nucleotide sequence of PRregion of plasma RNAvirus in a total of 128 patients, whose plasma viral load (VL) was 10,000 copies/ml or more at baseline. This study clearly demonstrated that examination of the Pl-resis- Current Status of HIV/AIDS in ACC tance at 3 months after the start of therapy is beneficial for PInai've patients to predict their prognosis if VLremained at 103 order/ml at that time (5) .
Opportunistic infections associated with HI V infection Treatment for HIVinfection consists of two major arms;
one is the use of anti-HIV drugs to prevent the development of AIDSas described above and the other is diagnosis, treatment, and prophylaxis of opportunistic infections. There are five very important opportunistic infections ; Pneumocystis carinii pneumonia (PCP), cryptococcus meningitis, toxoplasma encephalitis, cytomegalovirus (CMV) infection, and Mycobacterium avium complex (MAC)bacteremia. If these five infections can be precisely diagnosed, a patient can survive under the appropriate treatment. On the other hand, if these are not diagnosed, the patient will die of AIDS. After introducing HAART, the number of cases of CMVretinitis, MACbacteremia, and AIDS dementia complex was decreased. However, the number of PCP remained high because PCP is the first indicator disease of AIDS if the patient does not know his HIV status. The first choice of drug is sulfamethoxazole/trimethoprim (ST) for PCP treatment. If the patient is in severe respiratory failure, corticosteroid is used concomitantly. Treatment is usually continued for 3 weeks. Wehave successfully treated 45 out of47 cases of PCPfor 4 years. However, those patients treated with ST for 3 weeks were limited to only 35%due to the very high rate of side effects of ST (6) . If the patient was intolerant to ST, treatment was switched to pentamidine. After finishing the treatment, the patient is to be treated with a 5-day course of oral desensitization to ST (7) . Aprotocol of our method is shown in Table 1 . More than 80%of patients who were previously intolerant to ST successfully obtained tolerance by this method.
Future treatment
The main cause of immunodeficiency in HIV-patients is attributed to qualitative and quantitative abnormalities of CD4 lymphocytes. Wepreviously reported that the production of IL-2 from CD4lymphocytes in the advance stage of patients is significantly decreased (8) . IL-2 increases number and function of CD4lymphocytes. According to these properties of IL-2, the international clinical trial of subcutaneous administration of IL-2 is on going. This is one of the immune-based therapies administrating cytokines. Another immune-based approach is structured treatment interruptions (STI). This new strategy is to maintain the immunefunction to HIV by maintaining a ACChas a plan to start STI in primary infected patients. HAART can not cure HIV infection. Immune-based therapies which allow patients to long-term non-progressors will be used to support HAART in the future.
